Related Experiment Videos
Detection of minimal residual leukemia in acute lymphoblastic leukemia
Abstract:
Morphologic, immunologic, enzymatic and cytogenetic methods detect residual leukemic cells at the level of 5%. The early detection of leukemia by these methods has failed to improve outcome for children with residual disease. The use of molecular biologic techniques, particularly those involving the polymerase chain reaction, can detect 1 leukemic cell among 10,000 or even 100,000 normal cells. At this time, it is essential to conduct the proper clinical trials to determine the clinical utility of methods so sensitive and specific.
Insights
Sensitive molecular biologic techniques can detect minimal residual leukemia cells, but clinical trials are needed to confirm their benefit for improving childhood leukemia outcomes.
Area of Science:
- Hematology
- Molecular Biology
- Pediatric Oncology
Background:
- Current methods like morphology, immunology, and cytogenetics detect residual leukemia cells at 5%.
- These detection levels have not improved outcomes for children with residual leukemia.
- Highly sensitive molecular techniques offer potential for earlier and more precise detection.
Purpose of the Study:
- To evaluate the clinical utility of highly sensitive molecular biologic techniques for detecting minimal residual disease in leukemia.
- To determine if improved detection sensitivity can translate to better patient outcomes.
Main Methods:
- Utilizing molecular biologic techniques, specifically the polymerase chain reaction (PCR).
- Assessing the sensitivity of PCR in detecting leukemic cells at ratios of 1:10,000 to 1:100,000.
Main Results:
- Molecular methods, such as PCR, demonstrate a significantly higher sensitivity in detecting residual leukemic cells compared to conventional methods.
- These advanced techniques can identify leukemia at much lower levels, down to 1 leukemic cell among 10,000-100,000 normal cells.
Conclusions:
- The extreme sensitivity of molecular biologic techniques for detecting minimal residual disease in leukemia is established.
- Further clinical trials are crucial to ascertain the clinical utility and impact of these sensitive methods on patient outcomes.